iSTAR Medical continues market expansion with MINIject® in the UK

iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, today announced that it has further expanded its commercial rollout for MINIject® to the UK. MINIject® is iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) implant and currently the only commercially available supraciliary MIGS device. With this market expansion, patients in the UK with open angle glaucoma are now able to benefit from MINIject®, which has demonstrated meaningful and sustained performance, combined with a favorable safety profile.

The first implants with MINIject® have now been successfully completed at The Colchester Eye Centre of Excellence (UK) by Mr Chrys Dimitriou, Consultant Ophthalmic Surgeon in Cataract & Glaucoma and Specialist in MIGS.

Glaucoma is the leading cause of irreversible blindness affecting around 100 million people worldwide and approximately 10 million in Europe alone.1,2 MIGS represents the most promising and fastest-growing glaucoma therapy, due to its enhanced safety profile compared to traditional surgery.1

Chrys Dimitriou, Consultant Ophthalmic Surgeon in Cataract & Glaucoma and Specialist in MIGS, at The Colchester Eye Centre of Excellence, Colchester (UK) commented: “With over half a million individuals living with glaucoma in the UK, a number that will continue to grow with an ageing population, the need for effective and safe treatment options is more urgent than ever.3 MIGS implants represent an increasingly important way of preventing the progression of glaucoma. By targeting the supraciliary space, MINIject® aims to offer an impressive combination of favorable safety and powerful efficacy.”

Michel Vanbrabant, CEO of iSTAR Medical, commented: “Our commercial roll out across Europe is continuing as scheduled and we are delighted to add the important UK market. As the only commercially available MIGS device currently targeting the supraciliary space, we continue to receive positive feedback from surgeons on MINIject® and we look forward to supporting many more clinicians in providing the very best in MIGS treatment to their patients.”
MB Bureau